In the last decade, the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) drug class has revolutionized treatment for type 2 diabetes mellitus and some of its comorbidities, including obesity and cardiovascular disease. Continued advancements in the GLP-1 RA space show clinical promise for patients, though challenges-including barriers to care such as drug expense and availability-exist. This article provides an overview of available GLP-1 RAs and their mechanisms of action, indications, adverse reactions, and risks, providing practical pearls for providers along the way.
Keyphrases
- cardiovascular disease
- end stage renal disease
- rheumatoid arthritis
- type diabetes
- ejection fraction
- newly diagnosed
- healthcare
- chronic kidney disease
- metabolic syndrome
- insulin resistance
- adverse drug
- prognostic factors
- peritoneal dialysis
- disease activity
- weight loss
- wild type
- ankylosing spondylitis
- glycemic control
- systemic lupus erythematosus
- cardiovascular events
- combination therapy
- deep learning
- human health
- pain management
- physical activity
- replacement therapy
- electronic health record
- climate change